The global companion animal cardiac drugs market was estimated at USD 1.24 billion in 2025 and is projected to reach USD 3.18 billion by 2035, growing at a CAGR of 8.8% from 2026 to 2035. Growth is supported by rising pet populations, aging animals with higher cardiac disease risk, expanding evidence-based treatment options and owners seeking advanced care.
Market Highlights
North America held about 42% of the market in 2025.
Asia Pacific is expected to grow fastest, at a 12.1% CAGR.
Diuretics held about 28% share in 2025, while positive inotropes grow at 11.4% CAGR.
Dogs held about 74% share in 2025, while cats grow at 10.6% CAGR.
Myxomatous mitral valve disease (MMVD) held about 38% share in 2025; dilated cardiomyopathy grows at 9.8% CAGR.
Veterinary hospitals and clinics held about 61% of distribution share in 2025.
Growth Factors
Growing pet ownership, humanization of pet care and pet insurance uptake increase spending on cardiac diagnosis and long-term medication.
Cardiac disease is common in aging pets, including MMVD in small dogs, dilated cardiomyopathy in large dogs and hypertrophic cardiomyopathy in cats.
Pimobendan use has expanded into preclinical canine MMVD following trial evidence and updated ACVIM guidelines.
Spironolactone added to loop diuretic therapy is raising per-patient drug spending.
More veterinary cardiology specialists and better diagnostics enable earlier diagnosis.
Category Insights
Diuretics, led by furosemide, remain the largest drug type due to their central role in heart failure care and low generic cost. Dogs dominate animal demand because of higher cardiac disease prevalence. MMVD leads by indication because of its high prevalence and guideline-based management. Veterinary hospitals and clinics lead distribution because cardiac drugs are prescription-only, while online veterinary pharmacies are the fastest-growing channel at an estimated 16.8% CAGR.
Regional Analysis
North America
North America was estimated at USD 521 million in 2025 and is projected to reach about USD 1.27 billion by 2035, a 9.3% CAGR, supported by strong spending, a large specialist cardiology base and pet insurance.
Europe
Europe was estimated at USD 372 million in 2025 and is projected to reach about USD 880 million by 2035, a 9.0% CAGR, driven by high MMVD prevalence in breeds such as Cavalier King Charles Spaniels.
Asia Pacific
Asia Pacific is the fastest-growing region at a 12.1% CAGR, driven by pet ownership in China, Japan, South Korea and Australia. Japan is the most mature market in the region.
Middle East, Africa, and South and Central America
An emerging market, supported by pet ownership in Gulf countries and Brazil's large companion animal population.
Key Developments
October 2024: Boehringer Ingelheim Animal Health began a multicenter trial of pimobendan (Vetmedin) in cats with hypertrophic cardiomyopathy.
February 2025: Dechra Pharmaceuticals announced EMA acceptance of Cardisure Chewable Tablets, a palatable pimobendan chewable.
Meet the team
This report was prepared by our expert analysts with deep industry knowledge and hands-on research experience.
VJ
Veena Jagtap
Author · Healthcare Research Manager
A results-driven Healthcare Research Manager at Custom Market Insights, specializing in healthcare market intelligence, industry analysis, competitive benchmarking, and strategic market assessments. Experienced in managing end-to-end healthcare research projects, analyzing industry trends, evaluating competitive landscapes, and identifying emerging market opportunities across pharmaceuticals, biotechnology, medical devices, healthcare services, and life sciences.
Skilled in leading research initiatives, developing customized research methodologies, and transforming complex market data into actionable business insights. With a strong analytical mindset, strategic perspective, and commitment to research excellence, I focus on delivering accurate, data-driven intelligence that empowers clients to make informed business decisions, strengthen market positioning, and achieve sustainable growth in the evolving global healthcare industry.
Table of Contents
Explore the chapters covered in the full report.
Chapter 1. Report Introduction
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 USP & Key Offerings
1.2 Key Benefits For Stakeholders
1.3 Target Audience
1.4 Report Scope
Chapter 2. Market Overview
2.1 Market Definition & Scope
2.2 Key Market Takeaways
2.3 Market Snapshot
Chapter 3. Market Dynamics (DRO)
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Market Trends
Chapter 4. Companion Animal Cardiac Drugs Market - By drug type
4.1 Overview
4.2 Market Size & Forecast
Chapter 5. Companion Animal Cardiac Drugs Market - By animal type
By distribution channel: veterinary hospitals and clinics, retail veterinary pharmacies, online veterinary pharmacies, compounding pharmacies, other.
Frequently asked questions
What are the key driving factors influencing market growth?
Rising pet ownership, high cardiac disease prevalence in aging pets, evidence-based treatments such as pimobendan, expanding pet insurance coverage and guideline-driven prescribing.
Which region is expected to grow at the fastest CAGR?
Asia Pacific, at a 12.1% CAGR, driven by urban pet ownership, specialist veterinary services and growing insurance penetration.
Which region is anticipated to dominate the market?
North America, at about 42% in 2025, due to high veterinary spending and a large cardiology specialist base.
What is the projected market size by the end of the forecast period?
USD 3.18 billion by 2035, growing at a CAGR of 8.8% from 2026 to 2035.
Who are the key players in the Companion Animal Cardiac Drugs market?
Global Companion Animal Cardiac Drugs Market 2026 – 2035 — sample pages, full table of contents and the list of data tables, by email within one business day.